Interestingly, the therapeutic efficacy of GStemHep seems to be greater than or at least equivalent to that of primary human hepatocytes (100 vs. 60% survival, but not significantly different), which confirms that immature hepatic progenitors (AFP + ALB−) can be therapeutic for acute liver failure. The gene discussed is AFP; the disease is acute liver failure.